Liver Transplant Research Today is a free monthly online journal that collates and summarizes the latest research about Liver Transplant, including details on risks, prognosis, procedure, surgery, organ donation.

Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantation.

De Ruvo N, Cucchetti A, Lauro A, Masetti M, Di Benedetto F, Cautero N, La Barba G, Dazzi A, Di Francesco F, Molteni G, Romano A, Ramacciato G, Risaliti A, Pinna AD

Liver and Multiorgan Transplant Center, University of Bologna, Bologna, Italy.

Induction with thymoglobuline, a potent anti-thymocyte polyclonal antibody, has been recently reported to allow minimization of postoperative immunosuppression in organ transplantation. The relationship with recurrence of hepatitis C virus (HCV) after liver transplantation (LTx) has never been investigated. We report here on the outcome in 22 HCV+ patients receiving thymoglobuline pre-treatment and minimal immunosuppression after LTx. Patient survival and acute rejection rates were good, and remarkably low dosages and levels of immunosuppression were achieved with thymoglobuline, without exposing patients to an elevated risk of rejection. A progressive weaning of the primary immunosuppressor was also possible in the majority of patients without complications. The HCV recurrence rate was similar to what is reported in the literature, although lower HCV-RNA viral loads were obtained with thymoglobuline, with a mild histologic course. Although our results need to be validated in large cohort studies, our experience shows that minimization of immunosuppression with thymoglobuline is effective in protecting against rejection and demonstrated a positive impact on HCV recurrence that deserves further investigation.

Published 2 March 2005 in Clin Transplant, 19(2): 255-8.
Full-text of this article is available online (may require subscription).

© 2005-2008 Liver Transplant Research Today. All Rights Reserved.